Kinross Gold Corporation (NYSE:KGC) will release its fourth quarter and 2014 full-year financial statements and operating results on Tuesday, February 10, 2015, after market close. On Wednesday shares of Kinross Gold Corporation (NYSE:KGC) closed at $3.31. Company’s sales growth for last 5 years was 18.50%.
Micron Technology Inc (NASDAQ:MU) VP Brian Shirley sold 73,750 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $29.82, for a total transaction of $2,199,225.00. Following the completion of the transaction, the vice president now directly owns 319,030 shares in the company, valued at approximately $9,513,474.60. Micron Technology, Inc. (NASDAQ:MU) in last trading activity moved down -1.87% to close at $29.09. Company weekly performance is -4.58% while its quarterly performance stands at -9.92%. Micron Technology, Inc. (NASDAQ:MU) is -20.48% away from its 52 week high.
Oracle Corporation (NYSE:ORCL) wants to offer a low-cost, highly streamlined platform upon which companies can spark innovation, said Neil Mendelson, Vice President of Big Data at Oracle. His company plans to leverage the combination of Big Data framework Hadoop and Oracle’s own Exadata line of IT products to offer businesses the opportunity “to see a new insight or a new business model,” said Mendelson. On Wednesday shares of Oracle Corporation (NYSE:ORCL) closed at $42.69. Company’s sales growth for last 5 years was 10.50% and EPS growth for next 5 years is recorded as 8.50%.
Accuride Corp (NYSE:ACW) said Rick Dauch, its president and chief executive officer, has been elected for a three-year term to the Heavy Duty Manufacturers Association (HDMA) board of directors. Accuride Corp. (NYSE:ACW) has 0.20% insider ownership while its institutional ownership stands at 80.50%. In last trading activity company’s stock closed at $4.31.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) announced that the European Commission (EC) has sanctioned the Committee for Medicinal Products for Human Use’s (CHMP) recommendation regarding the use of Iclusig in its approved indications. With this endorsement, the European Article 20 review of Iclusig is complete. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) in last trading activity moved up 1.39% to close at $6.55. Company weekly performance is 7.03% while its quarterly performance stands at 14.11%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is -28.96% away from its 52 week high.